NDAINTRAVENOUSPOWDERPriority Review
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
Cytochrome P450 2C19 Inhibitors
Pharmacologic Class:
Lipoglycopeptide Antibacterial
Loss of Exclusivity
LOE Date
Jul 16, 2035
114 months away
Patent Expiry
Jul 16, 2035